Allogene Therapeutics Announces Participation in February Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…